Among Japanese pharmaceutical companies that have entered the domestic market, 4 out of 7 subsidiaries with settlements in March expanded their sales. Daiichi Sankyo Korea's sales reached 253.2 billion won, ranking first among Japanese pharmaceutical companies.

As a result of analyzing the performance for the 2022 business year (April 1, 2022, to March 31, 2023) of 7 pharmaceutical companies with settlements in March submitted to the Financial Supervisory Service on the 10th, the total sales amounted to KRW 1,115.4 billion, up from 11,557 in the previous year. decreased by 3% compared to the billion won. During the same period, operating profit fell 18% from 97.9 billion won to 80.2 billion won. 4 out